Literature DB >> 15464590

GPCR interacting proteins (GIP).

Joël Bockaert1, Laurent Fagni, Aline Dumuis, Philippe Marin.   

Abstract

G protein-coupled receptors (GPCR) interact not only with heterotrimeric G proteins but also with accessory proteins called GPCR interacting proteins (GIP). These proteins have important functions. They are implicated in GPCR targeting to specific cellular compartments, in their assembling into large functional complexes called "receptosomes," in their trafficking to and from the plasma membrane, and in the fine-tuning of their signaling properties. There are several types of GIPs. Some are transmembrane proteins such as another GPCR (homodimerization and heterodimerization), ionic channels, ionotropic receptors, and single transmembrane proteins. The latter is implicated in the fine-tuning of receptor pharmacology or signaling. Other GIPs are soluble proteins interacting mainly with the "magic" C-terminal tail. Among them, PDZ domain-containing proteins are the most abundant. They generally, but not always, interact with the extreme C-terminal domain of GPCRs. Some GIPs interact with specific sequences of the C-terminal such as the Homer binding sequence (-PPxxFR-), the dopamine receptor interacting protein (DRIP) binding sequence (-FxxxFxxxF-), etc. Finally, only few GIPs have been found thus far to interact with the third intracellular loop of GPCRs. The future will tell us if this situation is only due to technical reasons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464590     DOI: 10.1016/j.pharmthera.2004.06.004

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  77 in total

1.  Influence of the accessory protein SET on M3 muscarinic receptor phosphorylation and G protein coupling.

Authors:  Violaine Simon; Sukru S Oner; Joelle Cohen-Tannoudji; Andrew B Tobin; Stephen M Lanier
Journal:  Mol Pharmacol       Date:  2012-03-30       Impact factor: 4.436

2.  Molecular organization of the complex between the muscarinic M3 receptor and the regulator of G protein signaling, Gbeta(5)-RGS7.

Authors:  Simone L Sandiford; Qiang Wang; Konstantin Levay; Peter Buchwald; Vladlen Z Slepak
Journal:  Biochemistry       Date:  2010-06-22       Impact factor: 3.162

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

4.  Regulation of G protein-coupled receptor signaling: specific dominant-negative effects of melanocortin 2 receptor accessory protein 2.

Authors:  Julien A Sebag; Patricia M Hinkle
Journal:  Sci Signal       Date:  2010-04-06       Impact factor: 8.192

Review 5.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 6.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 7.  Ensemble of G protein-coupled receptor active states.

Authors:  P S-H Park
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

8.  Dynamic Na+-H+ exchanger regulatory factor-1 association and dissociation regulate parathyroid hormone receptor trafficking at membrane microdomains.

Authors:  Juan A Ardura; Bin Wang; Simon C Watkins; Jean-Pierre Vilardaga; Peter A Friedman
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

Review 9.  Optical probes based on G protein-coupled receptors - added work or added value?

Authors:  A D Stumpf; C Hoffmann
Journal:  Br J Pharmacol       Date:  2015-12-19       Impact factor: 8.739

Review 10.  The serotonin 5-HT7 receptors: two decades of research.

Authors:  Evelien Gellynck; Karen Heyninck; Kjetil W Andressen; Guy Haegeman; Finn Olav Levy; Peter Vanhoenacker; Kathleen Van Craenenbroeck
Journal:  Exp Brain Res       Date:  2013-09-17       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.